Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Cash from Operations (2016 - 2024)

Trinity Biotech's Cash from Operations history spans 16 years, with the latest figure at 3583000.0 for Q4 2024.

  • On a quarterly basis, Cash from Operations rose 1055.81% to 3583000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 1516000.0, a 208.99% increase, with the full-year FY2025 number at 5583000.0, down 33.21% from a year prior.
  • Cash from Operations hit 3583000.0 in Q4 2024 for Trinity Biotech, up from 310000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TRIB hit a ceiling of 14842000.0 in Q4 2020 and a floor of 4664000.0 in Q3 2023.
  • Historically, Cash from Operations has averaged 2766642.86 across 5 years, with a median of 1796000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 789.94% in 2023 and later skyrocketed 1055.81% in 2024.
  • Tracing TRIB's Cash from Operations over 5 years: stood at 14842000.0 in 2020, then crashed by 70.83% to 4330000.0 in 2021, then tumbled by 47.18% to 2287000.0 in 2022, then tumbled by 86.45% to 310000.0 in 2023, then skyrocketed by 1055.81% to 3583000.0 in 2024.
  • Business Quant data shows Cash from Operations for TRIB at 3583000.0 in Q4 2024, 310000.0 in Q4 2023, and 4664000.0 in Q3 2023.